# Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor

> **NCT06540937** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 50 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Leflunomide Pill

## Key facts

- **NCT ID:** NCT06540937
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06540937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06540937, "Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06540937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*